Improvement of verbal behavior after pharmacological treatment of developmental stuttering: a case study

Developmental stuttering is a disruption in normal speech fluency and rhythm. Developmental stuttering usually manifests between 6 and 9 years of age and may persist in adulthood. At present, the exact etiology of developmental stuttering is not fully clear. Besides, the dopaminergic neurological component is likely to have a causal role in the manifestation of stuttering behaviors. Actually, some studies seem to confirm the efficacy of antidopaminergic drugs (haloperidol, risperidone and olanzapine, among others) in controlling stuttering behaviors. We present a case of persistent developmental stuttering in a 24-year-old adult male who was able to control his symptoms to a significant extent after administration of risperidone, an antidopaminergic drug. Our findings show that the pharmacological intervention helped the patient improve on a set of fluency tasks but especially when the tasks involved the uttering of content words. Our results are discussed against the current theories on the cognitive and neurological basis of developmental stuttering.

[1]  P Howell,et al.  Exchange of stuttering from function words to content words with age. , 1999, Journal of speech, language, and hearing research : JSLHR.

[2]  J. Wu,et al.  Increased dopamine activity associated with stuttering , 1997, Neuroreport.

[3]  G. Riley,et al.  A neurological basis of stuttering? , 2002, The Lancet Neurology.

[4]  L A Gottschalk,et al.  Risperidone for the treatment of stuttering. , 2000, Journal of clinical psychopharmacology.

[5]  N J Cox,et al.  The genetic basis of persistence and recovery in stuttering. , 1997, Journal of speech, language, and hearing research : JSLHR.

[6]  E. Yairi,et al.  Genetics of stuttering: a critical review. , 1996, Journal of speech and hearing research.

[7]  S B Leder Adult onset of stuttering as a presenting sign in a parkinsonian-like syndrome: a case report. , 1996, Journal of communication disorders.

[8]  Tim J Anderson,et al.  Tics and developmental stuttering. , 2003, Parkinsonism & related disorders.

[9]  R. Kroll,et al.  Stuttering: an update for physicians. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  R E Carson,et al.  Altered patterns of cerebral activity during speech and language production in developmental stuttering. An H2(15)O positron emission tomography study. , 1997, Brain : a journal of neurology.

[11]  Gerald Maguire,et al.  Management of Child and Adolescent Stuttering with Olanzapine: Three Case Reports , 1999, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[12]  H. Dorn,et al.  Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. Vol. I , 1950 .

[13]  B. Schneider MANUAL of the international statistical classification of diseases, injuries, and causes of death. Addendum 1. Supplementary interpretations and instructions for coding causes of death. , 1953, Bulletin of the World Health Organization. Supplement.

[14]  S. Schreiber,et al.  Paroxetine for secondary stuttering: further interaction of serotonin and dopamine. , 1997, The Journal of nervous and mental disease.

[15]  Frank Wijnen,et al.  Stuttering and speech monitoring , 2001, DiSS.